We have demonstrated for the first time that AP-mediated upregulation of METTL3 alleviates AD by enhancing the BDNF/TrkB pathway and inhibiting inflammation through an m6A-dependent reduction in BDNF-AS transcripts (Figure 8). Here, METTL3 is linked to Alzheimer disease.